ArticleLupus science & medicine2025
Prevalence, sociodemographic characteristics and spatial distribution of systemic lupus erythematosus in France: a nationwide study using health claims data with insights into hydroxychloroquine prescription patterns.
Article in Lupus science & medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveOur primary objective was to estimate an updated prevalence of SLE in France in 2020. We also explore the sociodemographic characteristics of patients with SLE, the social and spatial variability and also study and use hydroxychloroquine prescription patterns as an external validation for case ascertainment.
methodsWe used the French national health data system, which covers almost all of the 67 million people living in France. Prevalent cases were identified among inpatients and people granted a long-term disease status, using the International Classification of Diseases, 10th Revision code for SLE. Filled prescriptions of hydroxychloroquine were also counted.
resultsIn 2020, we identified 54 804 patients with SLE; this corresponds to an overall prevalence of 81.6 per 100 000 people. The prevalence estimates were 137.0 per 100 000 in women and 22.5 per 100 000 in men. The highest standardised prevalences were observed in the French overseas departments and in the mainland departments to which people from these departments frequently migrate. Unexpectedly, we did not find an association between the prevalence of SLE in mainland France and a social deprivation index. A prescription of hydroxychloroquine was filled at least once for 67.7% of the patients overall and reached 86.7% of those aged between 20 and 24.
conclusionsOur study provides recent, accurate estimates of the prevalence and social and geographical distribution of SLE in France. We observed an almost twofold increase in prevalence, relative to a previous estimate (from 2010) based on the same database. The high proportion of patients receiving a prescription of hydroxychloroquine is in line with current treatment guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.